Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 0
---
FILED PURSUANT TO RULE 424(b)(3)

Registration No. 333-284007

PROSPECTUS

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

300,000 Shares of Common Stock

2,251,020 Pre-Funded Warrants to Purchase 2,251,020 Shares of Common Stock

2,551,020 Common Warrants to Purchase 2,551,020 Shares of Common Stock

4,802,040 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrants and Common Warrants</div>

We are offering 300,000 shares of our common stock, par value $0.0001 per share (“Common Stock”), together with 2,551,020 new common warrants (the “Offered Common Warrants”) to purchase up to an aggregate of 2,551,020 shares of our Common Stock and an aggregate of 2,551,020 shares of our Common Stock issuable upon exercise of the Offered Common Warrants. Each share of Common Stock, or pre-funded warrant in lieu thereof (“Pre-Funded Warrants”), is being sold together with an Offered Common Warrant to purchase one share of Common Stock.

The public offering price for each share of Common Stock and accompanying Offered Common Warrant is $1.96, which was the closing price of our Common Stock on the Nasdaq Capital Market (the “Nasdaq”) on February 5, 2025. Each Offered Common Warrant will have an exercise price per share of $1.96 and will be immediately exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Offered Common Warrants (the “Warrant Stockholder Approval”). The Offered Common Warrants will expire on the 5-year anniversary of the Warrant Stockholder Approval.

We are also offering to certain purchasers whose purchase of shares of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, Pre-Funded Warrants to purchase up to 2,251,020 shares of Common Stock, in lieu of shares of Common Stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99